IFIH1 and myositis disease: In addition, prospective clinical trials based on the stratification of MSA status, especially those presenting with anti-MDA5 antibody-positive or anti-ARS antibody-positive, is needed in order to elucidate evidence-based treatment approaches in various phenotypes of myositis-associated-ILD.